Trials / Active Not Recruiting
Active Not RecruitingNCT04126525
Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
NeoAdjuvant Trastuzumab/ Pyrotinib Plus Weekly Paclitaxel/Cisplatin in HER2-positive Locally Advanced Breast Cancer Patients
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open label study to evaluate the efficacy and safety of neoadjuvant pyrotinib in early breast cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyrotinib | dual HER2 blockade in the neoadjuvant setting |
Timeline
- Start date
- 2019-06-18
- Primary completion
- 2021-10-28
- Completion
- 2026-11-01
- First posted
- 2019-10-15
- Last updated
- 2025-09-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04126525. Inclusion in this directory is not an endorsement.